Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

Myostatin Inhibition Using ActRIIB-mFc Does Not Produce Weight Gain or Strength in the Nebulin Conditional KO Mouse.

Tinklenberg JA, Siebers EM, Beatka MJ, Fickau BA, Ayres S, Meng H, Yang L, Simpson P, Granzier HL, Lawlor MW.

J Neuropathol Exp Neurol. 2019 Feb 1;78(2):130-139. doi: 10.1093/jnen/nly120.

PMID:
30597051
2.

Use Of Ankle Immobilization In Evaluating Treatments To Promote Longitudinal Muscle Growth In Mice.

Tinklenberg J, Beatka M, Bain JLW, Siebers EM, Meng H, Pearsall RS, Lawlor MW, Riley DA.

Muscle Nerve. 2018 Nov;58(5):718-725. doi: 10.1002/mus.26296. Epub 2018 Oct 2.

PMID:
29981243
3.

Sdha+/- Rats Display Minimal Muscle Pathology Without Significant Behavioral or Biochemical Abnormalities.

Siebers EM, Choi MJ, Tinklenberg JA, Beatka MJ, Ayres S, Meng H, Helbling DC, Takizawa A, Bennett B, Garces AM, Dias Duarte Machado LG, Dimmock D, Dwinell MR, Geurts AM, Lawlor MW.

J Neuropathol Exp Neurol. 2018 Aug 1;77(8):665-672. doi: 10.1093/jnen/nly042.

4.

Myostatin inhibition using mRK35 produces skeletal muscle growth and tubular aggregate formation in wild type and TgACTA1D286G nemaline myopathy mice.

Tinklenberg JA, Siebers EM, Beatka MJ, Meng H, Yang L, Zhang Z, Ross JA, Ochala J, Morris C, Owens JM, Laing NG, Nowak KJ, Lawlor MW.

Hum Mol Genet. 2018 Feb 15;27(4):638-648. doi: 10.1093/hmg/ddx431.

5.

Assessing adult attention deficit hyperactivity disorder (ADHD) in the university setting.

Tinklenberg J, Patel B, Gelman K, Albucher R.

J Am Coll Health. 2018 Feb-Mar;66(2):141-144. doi: 10.1080/07448481.2017.1389733. Epub 2017 Nov 21.

PMID:
29028463
6.

Treatment with ActRIIB-mFc Produces Myofiber Growth and Improves Lifespan in the Acta1 H40Y Murine Model of Nemaline Myopathy.

Tinklenberg J, Meng H, Yang L, Liu F, Hoffmann RG, Dasgupta M, Allen KP, Beggs AH, Hardeman EC, Pearsall RS, Fitts RH, Lawlor MW.

Am J Pathol. 2016 Jun;186(6):1568-81. doi: 10.1016/j.ajpath.2016.02.008. Epub 2016 Apr 18.

7.

Donepezil treatment in ethnically diverse patients with Alzheimer disease.

Tinklenberg JR, Kraemer HC, Yaffe K, O'Hara R, Ringman JM, Ashford JW, Yesavage JA, Taylor JL; California Alzheimer's Disease Centers.

Am J Geriatr Psychiatry. 2015 Apr;23(4):384-390. doi: 10.1016/j.jagp.2014.09.007. Epub 2014 Sep 28.

8.

Memantine is associated with longer survival than donepezil in a Veterans Affairs prescription database, 1997 to 2008.

Lazzeroni LC, Halbauer JD, Ashford JW, Noda A, Hernandez B, Azor V, Hozack N, Hasson N, Henderson VW, Yesavage JA, Tinklenberg JR.

J Alzheimers Dis. 2013;36(4):791-8. doi: 10.3233/JAD-130662.

PMID:
23703151
9.

Walking stabilizes cognitive functioning in Alzheimer's disease (AD) across one year.

Winchester J, Dick MB, Gillen D, Reed B, Miller B, Tinklenberg J, Mungas D, Chui H, Galasko D, Hewett L, Cotman CW.

Arch Gerontol Geriatr. 2013 Jan-Feb;56(1):96-103. doi: 10.1016/j.archger.2012.06.016. Epub 2012 Sep 5.

10.

Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans.

Bakken TE, Roddey JC, Djurovic S, Akshoomoff N, Amaral DG, Bloss CS, Casey BJ, Chang L, Ernst TM, Gruen JR, Jernigan TL, Kaufmann WE, Kenet T, Kennedy DN, Kuperman JM, Murray SS, Sowell ER, Rimol LM, Mattingsdal M, Melle I, Agartz I, Andreassen OA, Schork NJ, Dale AM; Alzheimer's Disease Neuroimaging Initiative; Pediatric Imaging, Neurocognition, and Genetics Study, Weiner M, Aisen P, Petersen R, Jack CR Jr, Jagust W, Trojanowki JQ, Toga AW, Beckett L, Green RC, Saykin AJ, Morris J, Liu E, Montine T, Gamst A, Thomas RG, Donohue M, Walter S, Gessert D, Sather T, Harvey D, Kornak J, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Bandy D, Koeppe RA, Foster N, Reiman EM, Chen K, Mathis C, Cairns NJ, Taylor-Reinwald L, Trojanowki JQ, Shaw L, Lee VM, Korecka M, Crawford K, Neu S, Foroud TM, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder PJ, Molchan S, Kaye J, Quinn J, Lind B, Dolen S, Schneider LS, Pawluczyk S, Spann BM, Brewer J, Vanderswag H, Heidebrink JL, Lord JL, Johnson K, Doody RS, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig LS, Bell KL, Morris JC, Ances B, Carroll M, Leon S, Mintun MA, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Mitsis E, Romirowsky A, deToledo-Morrell L, Shah RC, Duara R, Varon D, Roberts P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon MJ, Glodzik L, De Santi S, Doraiswamy PM, Petrella JR, Coleman RE, Arnold SE, Karlawish JH, Wolk D, Smith CD, Jicha G, Hardy P, Lopez OL, Oakley M, Simpson DM, Porsteinsson AP, Goldstein BS, Martin K, Makino KM, Ismail MS, Brand C, Mulnard RA, Thai G, Mc-Adams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, Martin-Cook K, DeVous M, Levey AI, Lah JJ, Cellar JS, Burns JM, Anderson HS, Swerdlow RH, Apostolova L, Lu PH, Bartzokis G, Silverman DH, Graff-Radford NR, Parfitt F, Johnson H, Farlow MR, Hake AM, Matthews BR, Herring S, van Dyck CH, Carson RE, MacAvoy MG, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Ging-Yuek, Hsiung R, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam MM, Lipowski K, Wu CK, Johnson N, Sadowsky C, Martinez W, Villena T, Turner RS, Johnson K, Reynolds B, Sperling RA, Johnson KA, Marshall G, Frey M, Yesavage J, Taylor JL, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson AE, Norbash A, Johnson PL, Obisesan TO, Wolday S, Bwayo SK, Lerner A, Hudson L, Ogrocki P, Fletcher E, Carmichael O, Olichney J, Kittur S, Borrie M, Lee TY, Bartha R, Johnson S, Asthana S, Carlsson CM, Potkin SG, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre DW, Kataki M, Zimmerman EA, Celmins D, Brown AD, Pearlson GD, Blank K, Anderson K, Santulli RB, Schwartz ES, Sink KM, Williamson JD, Garg P, Watkins F, Ott BR, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen HJ, Miller BL, Mintzer J, Longmire CF, Spicer K, Finger E, Rachinsky I, Drost D, Jernigan T, McCabe C, Grant E, Ernst T, Kuperman J, Chung Y, Murray S, Bloss C, Darst B, Pritchett L, Saito A, Amaral D, DiNino M, Eyngorina B, Sowell E, Houston S, Soderberg L, Kaufmann W, van Zijl P, Rizzo-Busack H, Javid M, Mehta N, Ruberry E, Powers A, Rosen B, Gebhard N, Manigan H, Frazier J, Kennedy D, Yakutis L, Hill M, Gruen J, Bosson-Heenan J, Carlson H.

Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3985-90. doi: 10.1073/pnas.1105829109. Epub 2012 Feb 16.

11.

Circadian clock gene polymorphisms and sleep-wake disturbance in Alzheimer disease.

Yesavage JA, Noda A, Hernandez B, Friedman L, Cheng JJ, Tinklenberg JR, Hallmayer J, O'hara R, David R, Robert P, Landsverk E, Zeitzer JM; Alzheimer's Disease Neuroimaging Initiative.

Am J Geriatr Psychiatry. 2011 Jul;19(7):635-43. doi: 10.1097/JGP.0b013e31820d92b2.

12.

Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice?

Tinklenberg JR, Kraemer HC, Yaffe K, Ross L, Sheikh J, Ashford JW, Yesavage JA, Taylor JL.

Am J Geriatr Psychiatry. 2007 Nov;15(11):953-60.

PMID:
17974866
13.

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.

Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T.

Nat Med. 2007 Nov;13(11):1359-62. Epub 2007 Oct 14.

PMID:
17934472
14.

Statistical and pharmacoeconomic issues for Alzheimer's screening.

Ashford JW, Kraemer HC, Tinklenberg JR, O'Hara R, Taylor JL, Yesavage JA.

Alzheimers Dement. 2007 Apr;3(2):126; discussion 127-31. doi: 10.1016/j.jalz.2007.03.004. No abstract available.

PMID:
19595924
15.

Factors associated with use of medications with potential to impair cognition or cholinesterase inhibitors among Alzheimer's disease patients.

Huey ED, Taylor JL, Luu P, Oehlert J, Tinklenberg JR.

Alzheimers Dement. 2006 Oct;2(4):314-21. doi: 10.1016/j.jalz.2006.08.003.

16.

Caution regarding the use of pilot studies to guide power calculations for study proposals.

Kraemer HC, Mintz J, Noda A, Tinklenberg J, Yesavage JA.

Arch Gen Psychiatry. 2006 May;63(5):484-9.

PMID:
16651505
17.

The brain-derived neurotrophic factor Val66Met polymorphism and rate of decline in Alzheimer's disease.

Chuu JY, Taylor JL, Tinklenberg J, Noda A, Yesavage J, Murphy GM Jr.

J Alzheimers Dis. 2006 Mar;9(1):43-9.

PMID:
16627933
18.

Spatial test for agricultural pesticide "blow-in" effect on prevalence of Parkinson's disease.

Yesavage JA, Sheikh J, Noda A, Murphy G, O'Hara R, Hierholzer R, Battista M, Ashford JW, Schneider B, Hoblyn J, Kraemer HC, Tinklenberg J.

J Geriatr Psychiatry Neurol. 2006 Mar;19(1):32-5.

PMID:
16449758
19.

Factors in choosing atypical antipsychotics: toward understanding the bases of physicians' prescribing decisions.

Hoblyn J, Noda A, Yesavage JA, Brooks JO 3rd, Sheikh J, Lee T, Tinklenberg JR, Schneider B, O'Hara R, Leslie DL, Rosenheck RA, Kraemer HC.

J Psychiatr Res. 2006 Mar;40(2):160-6. Epub 2005 Sep 8.

PMID:
16150458
20.

Tolerability and effectiveness of lamotrigine in complex elderly patients.

Aulakh JS, Hawkins JW, Athwal HS, Sheikh JI, Yesavage J, Tinklenberg JR.

J Geriatr Psychiatry Neurol. 2005 Mar;18(1):8-11.

PMID:
15681622
21.

Validation of a 26-point telephone version of the Mini-Mental State Examination.

Newkirk LA, Kim JM, Thompson JM, Tinklenberg JR, Yesavage JA, Taylor JL.

J Geriatr Psychiatry Neurol. 2004 Jun;17(2):81-7.

PMID:
15157348
22.

Use of a VA pharmacy database to screen for areas at high risk for disease: Parkinson's disease and exposure to pesticides.

Yesavage JA, Sheikh J, Noda A, Murphy G, O'Hara R, Hierholzer R, Battista M, Ashford JW, Kraemer HC, Tinklenberg J.

J Geriatr Psychiatry Neurol. 2004 Mar;17(1):36-8.

PMID:
15018696
23.

Sleep/wake disruption in Alzheimer's disease: APOE status and longitudinal course.

Yesavage JA, Friedman L, Kraemer H, Tinklenberg JR, Salehi A, Noda A, Taylor JL, O'Hara R, Murphy G.

J Geriatr Psychiatry Neurol. 2004 Mar;17(1):20-4.

PMID:
15018693
24.

Age and disease severity predict choice of atypical neuroleptic: a signal detection approach to physicians' prescribing decisions.

Yesavage JA, Hoblyn J, Sheikh J, Tinklenberg JR, Noda A, O'Hara R, Fenn C, Mumenthaler MS, Friedman L, Kraemer HC.

J Psychiatr Res. 2003 Nov-Dec;37(6):535-8.

PMID:
14563385
25.

Which Alzheimer patients are at risk for rapid cognitive decline?

O'Hara R, Thompson JM, Kraemer HC, Fenn C, Taylor JL, Ross L, Yesavage JA, Bailey AM, Tinklenberg JR.

J Geriatr Psychiatry Neurol. 2002 Winter;15(4):233-8.

PMID:
12489920
26.

On disentangling states versus traits: demonstration of a new technique using the Alzheimer's disease assessment scale.

Taylor JL, Kraemer HC, Noda A, Friedman L, Zarcone V, Tinklenberg JR, Yesavage JA.

Alzheimer Dis Assoc Disord. 2002 Oct-Dec;16(4):254-60.

PMID:
12468900
27.

Donepezil and flight simulator performance: effects on retention of complex skills.

Yesavage JA, Mumenthaler MS, Taylor JL, Friedman L, O'Hara R, Sheikh J, Tinklenberg J, Whitehouse PJ.

Neurology. 2002 Jul 9;59(1):123-5.

PMID:
12105320
28.

Sleep/wake cycle disturbance in Alzheimer's disease: how much is due to an inherent trait?

Yesavage JA, Taylor JL, Kraemer H, Noda A, Friedman L, Tinklenberg JR.

Int Psychogeriatr. 2002 Mar;14(1):73-81.

PMID:
12094910
29.

Rate of cognitive decline in AD is accelerated by the interleukin-1 alpha -889 *1 allele.

Murphy GM Jr, Claassen JD, DeVoss JJ, Pascoe N, Taylor J, Tinklenberg JR, Yesavage JA.

Neurology. 2001 Jun 12;56(11):1595-7.

PMID:
11402127
30.

Remote memory for public figures in Alzheimer's disease: relationships to regional cortical and limbic brain volumes.

Fama R, Shear PK, Marsh L, Yesavage JA, Tinklenberg JR, Lim KO, Pfefferbaum A, Sullivan EV.

J Int Neuropsychol Soc. 2001 Mar;7(3):384-90.

PMID:
11311039
31.

Event-related brain potential evidence of spared knowledge in Alzheimer's disease.

Ford JM, Askari N, Mathalon DH, Menon V, Gabrieli JD, Tinklenberg JR, Yesavage J.

Psychol Aging. 2001 Mar;16(1):161-76.

PMID:
11302364
32.

A retrospective chart review of gabapentin for the treatment of aggressive and agitated behavior in patients with dementias.

Hawkins JW, Tinklenberg JR, Sheikh JI, Peyser CE, Yesavage JA.

Am J Geriatr Psychiatry. 2000 Summer;8(3):221-5.

PMID:
10910420
33.

Extent, pattern, and correlates of remote memory impairment in Alzheimer's disease and Parkinson's disease.

Fama R, Sullivan EV, Shear PK, Stein M, Yesavage JA, Tinklenberg JR, Pfefferbaum A.

Neuropsychology. 2000 Apr;14(2):265-76.

PMID:
10791866
34.

Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF.

Kahle PJ, Jakowec M, Teipel SJ, Hampel H, Petzinger GM, Di Monte DA, Silverberg GD, Möller HJ, Yesavage JA, Tinklenberg JR, Shooter EM, Murphy GM Jr.

Neurology. 2000 Apr 11;54(7):1498-504.

PMID:
10751266
35.

Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability.

Chui HC, Mack W, Jackson JE, Mungas D, Reed BR, Tinklenberg J, Chang FL, Skinner K, Tasaki C, Jagust WJ.

Arch Neurol. 2000 Feb;57(2):191-6.

PMID:
10681076
36.

Structural brain correlates of verbal and nonverbal fluency measures in Alzheimer's disease.

Fama R, Sullivan EV, Shear PK, Cahn-Weiner DA, Marsh L, Lim KO, Yesavage JA, Tinklenberg JR, Pfefferbaum A.

Neuropsychology. 2000 Jan;14(1):29-40.

PMID:
10674796
37.

Alpha2 macroglobulin and the risk of Alzheimer's disease.

Dodel RC, Du Y, Bales KR, Gao F, Eastwood B, Glazier B, Zimmer R, Cordell B, Hake A, Evans R, Gallagher-Thompson D, Thompson LW, Tinklenberg JR, Pfefferbaum A, Sullivan EV, Yesavage J, Alstiel L, Gasser T, Farlow MR, Murphy GM Jr, Paul SM.

Neurology. 2000 Jan 25;54(2):438-42.

PMID:
10668709
38.

Convergent behavioral and neuropsychological evidence for a distinction between identification and production forms of repetition priming.

Gabrieli JD, Vaidya CJ, Stone M, Francis WS, Thompson-Schill SL, Fleischman DA, Tinklenberg JR, Yesavage JA, Wilson RS.

J Exp Psychol Gen. 1999 Dec;128(4):479-98.

PMID:
10650584
39.

Brain structural and cognitive correlates of clock drawing performance in Alzheimer's disease.

Cahn-Weiner DA, Sullivan EV, Shear PK, Fama R, Lim KO, Yesavage JA, Tinklenberg JR, Pfefferbaum A.

J Int Neuropsychol Soc. 1999 Sep;5(6):502-9.

PMID:
10561930
40.

Dissociation between two forms of conceptual priming in Alzheimer's disease.

Vaidya CJ, Gabrieli JD, Monti LA, Tinklenberg JR, Yesavage JA.

Neuropsychology. 1999 Oct;13(4):516-24.

PMID:
10527059
41.

Taking account of between-patient variability when modeling decline in Alzheimer's disease.

Joseph L, Wolfson DB, Bélisle P, Brooks JO 3rd, Mortimer JA, Tinklenberg JR, Yesavage JA.

Am J Epidemiol. 1999 May 15;149(10):963-73.

PMID:
10342806
42.

The stages of Alzheimer's disease: a reappraisal.

Kraemer HC, Taylor JL, Tinklenberg JR, Yesavage JA.

Dement Geriatr Cogn Disord. 1998 Nov-Dec;9(6):299-308.

PMID:
9769442
43.

A follow-up study of actigraphic measures in home-residing Alzheimer's disease patients.

Yesavage JA, Friedman L, Kraemer HC, Noda A, Wicks D, Bliwise DL, Sheikh J, Tinklenberg J, Zarcone V.

J Geriatr Psychiatry Neurol. 1998 Spring;11(1):7-10.

PMID:
9686746
44.

Preserved priming across study-test picture transformations in patients with Alzheimer's disease.

Park SM, Gabrieli JD, Reminger SL, Monti LA, Fleischman DA, Wilson RS, Tinklenberg JR, Yesavage JA.

Neuropsychology. 1998 Jul;12(3):340-52.

PMID:
9673992
45.

Cognitive and noncognitive symptoms in dementia patients: relationship to cortisol and dehydroepiandrosterone.

Miller TP, Taylor J, Rogerson S, Mauricio M, Kennedy Q, Schatzberg A, Tinklenberg J, Yesavage J.

Int Psychogeriatr. 1998 Mar;10(1):85-96.

PMID:
9629527
46.

Structural MRI correlates of recognition memory in Alzheimer's disease.

Cahn DA, Sullivan EV, Shear PK, Marsh L, Fama R, Lim KO, Yesavage JA, Tinklenberg JR, Pfefferbaum A.

J Int Neuropsychol Soc. 1998 Mar;4(2):106-14.

PMID:
9529820
47.

Selective cortical and hippocampal volume correlates of Mattis Dementia Rating Scale in Alzheimer disease.

Fama R, Sullivan EV, Shear PK, Marsh L, Yesavage JA, Tinklenberg JR, Lim KO, Pfefferbaum A.

Arch Neurol. 1997 Jun;54(6):719-28.

PMID:
9193207
48.

Cognitive function and the costs of Alzheimer disease. An exploratory study.

Ernst RL, Hay JW, Fenn C, Tinklenberg J, Yesavage JA.

Arch Neurol. 1997 Jun;54(6):687-93.

PMID:
9193203
49.

No association between the alpha 1-antichymotrypsin A allele and Alzheimer's disease.

Murphy GM Jr, Sullivan EV, Gallagher-Thompson D, Thompson LW, van Duijn CM, Forno LS, Ellis WG, Jagust WJ, Yesavage J, Tinklenberg JR.

Neurology. 1997 May;48(5):1313-6.

PMID:
9153464
50.

No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease.

Murphy GM Jr, Taylor J, Kraemer HC, Yesavage J, Tinklenberg JR.

Am J Psychiatry. 1997 May;154(5):603-8.

PMID:
9137113

Supplemental Content

Loading ...
Support Center